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Abstract
Urothelial carcinoma (UC) of the lower urinary tract and prostatic carcinoma (PC) are
aggressive genitourinary cancers in dogs, characterized by invasion to surrounding tissues
and high metastatic potential. Current diagnosis of canine UC and PC requires histopatho-
logical examination of a biopsy. Such specimens require specialized medical equipment
and are invasive procedures, limiting the availability of diagnosis by histopathology for
many canine patients. Access to a non-invasive means to confirm diagnosis is currently an
unmet need. Recently, the canine BRAF V595E mutation was detected in ~80% of canine
UCs and PCs. In this study, we developed a droplet digital PCR (ddPCR) assay for detec-
tion of the canine BRAF V595E mutation in canine urogenital tumors. The assay was evalu-
ated in DNA samples prepared from biopsy specimens of UC (n = 48) and PC (n = 27), as
well and non-neoplastic bladder epithelium (n = 38). In addition the assay was assessed for
use with DNA isolated from free catch urine samples derived from canine patients with UC
(n = 23), PC (n = 3), as well as from dogs with cystitis and healthy controls (n = 37). In all
cases the sensitivity to detect the mutant allele was compared with conventional Sanger
sequencing. ddPCR had superior sensitivity for detection of the V595E mutation: 75% of
UC, 85% of PC, and 0% of control samples were mutation positive, respectively, and the
V595E mutation was detected at a level as low as just 1 in 10,000 alleles (~0.01%). Further-
more, the ddPCR assay identified the mutation in free catch urine samples from 83% of
canine UC and PC patients, demonstrating its utility as a non-invasive means of diagnosis.
We have shown that ddPCR is a sensitive molecular technique with the potential to facilitate
accurate and non-invasive means of canine UC and PC diagnosis.
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Introduction
Urothelial carcinoma (UC) of the lower urinary tract and prostatic carcinoma (PC) in dogs are
characterized by local invasion and high rates of regional and distant metastases. The aggres-
siveness of these tumors is thought, at least in part, to result from delayed diagnosis and thera-
peutic intervention. Clinical symptoms of these genitourinary cancers, including hematuria,
stranguria and incontinence, are indistinguishable from other non-neoplastic and more com-
mon conditions such as cystitis and prostatitis [1–3]. Currently, reliable tests to distinguish UC
and PC from differential diagnoses are limited to histopathologic evaluation, requiring an inva-
sive and costly biopsy. In addition, the size and sex of affected dogs may limit the viability of
such diagnostics in individual patients, while the necessary skills and equipment may not be
available in all veterinary clinics [4]. Prompt diagnosis of genitourinary cancers therefore pres-
ents a clinical challenge to veterinarians, potentially impeding the timeline of appropriate
therapy.
Less invasive diagnostic aides for canine genitourinary cancers are available, though these
are considered unreliable. The presence of abnormal epithelial cells in urine sediment, trau-
matic catheterization, prostatic wash and/or fine needle aspiration have all been used to sup-
port the diagnosis of canine UC and PC [3–5]. Cytological analysis of epithelial cells, however,
may be misleading. For example, benign epithelial cells can appear morphologically neoplastic,
with variation in cell size and increased basophilia; after prolonged contact with urine or under
urothelial hyperplasia secondary to inflammatory condition [6]. Fine needle aspiration of
tumor tissue carries the risk of disseminating tumor cells along the needle tract and should be
performed with caution [7,8]. Currently, clinical diagnosis of canine UC and PC requires com-
prehensive diagnostic workups, including blood test, urinalysis and diagnostic imaging, in
addition to cytological examinations of tumor cells by skilled clinical pathologists [4,9]. The
availability of a reliable, non-invasive diagnostic test for canine UC and PC remains a para-
mount need.
Recent studies identified a somatic mutation in the canine BRAF (cBRAF) gene in several
canine cancers, including a large proportion of canine UC and PC [10,11]. The mutation was a
single nonsynonymous substitution of T to A at nucleotide 1784, resulting in the amino acid
substitution from valine to glutamic acid at codon 595 (V595E, based on cBRAF reference
sequence: Ensemble Transcript ID: ENSCAFT00000006306). Among various types of cancers
of epithelial, messenchymal, hematopoitiec and other cancers of miscellaneous origin, the stud-
ies identified the V595E mutation in canine UC and PC with the highest penetrance rates of up
to 87%. Since UC and PC tumor cells often exfoliate and shed into urine, the presence of the
V595E mutation in urine can be a molecular diagnostic marker [12].
Despite the high prevalence of the cBRAFmutation, there are technical challenges in detect-
ing the mutation in urine samples of canine UC and PC patients. Secondary bacterial cystitis is
common in dogs with UC and PC, recruiting a large number of inflammatory cells and reactive
epithelial cells and resulting in dilution of the shed tumor cell population in urine [4,9]. Sanger
sequencing, the gold standard for detecting a single nucleotide substitution, requires a 10–20%
fraction of mutated allele for reliable detection [13]. This low sensitivity leads to false negative
results in a mixed cell population, such as urine samples with low neoplastic cellularity.
Digital PCR is a highly sensitive molecular technique enabling detection of a “rare”mutated
sequence in clinical samples such as tumor DNA in plasma cell-free DNA, or, in this case,
urine [14–16]. Digital PCR is performed by partitioning the PCR mixtures into a large number
of compartments (e.g. droplets), where each compartment contains either 1 (positive) or 0
(negative) target sequences. After conventional thermal cycling amplification, each compart-
ment is classified as being either positive or negative by assessment of the fluorescence signal
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intensity at the end point. Wild type and mutant alleles are detected in the same reactions,
using spectrally resolvable fluorochromes. The numbers of positive and negative compart-
ments for each fluorochrome, together with Poisson’s distribution, are used to calculate abso-
lute number of target sequence in a sample without the need for calibration standards.
In this study, we developed a ddPCR-based cBRAF V595E mutation detection assay. With
the ddPCR assay, we examined the presence of the V595E mutation in tissue and urine samples
from dogs diagnosed with UC, PC, and in nonneoplastic control samples.
Materials and Methods
Tissue samples
All tissue and urine specimens used in this study were obtained by the North Carolina State
University (NCSU) Histology Lab or Clinical Studies Core, following NCSU IACUC approved
protocol No. 13-022-O, which included written informed consent from owners approving use
in research studies. Genomic DNA (gDNA) from 48 UC (n = 48), 27 PC (n = 27), and control
bladder tissues (n = 30 as normal n = 26, cystitis n = 3 and urothelial hyperplasia n = 1), and
control prostate gland (all normal, n = 8) was included in the present study. These gDNA sam-
ple were derived from the archive of our previous study [11], supplemented with five additional
(3 UC and 2 PC) DNA samples derived from additional formalin-fixed paraffin-embedded
(FFPE) blocks of tumor tissues obtained through North Carolina State University (NCSU) His-
tology Lab. gDNA was isolated from FFPE blocks using a QIAamp FFPE DNA extraction kit
(Qiagen, Valencia, CA). Spectrophotometry (NanoDrop, Thermo Scientific, Wilmington, DE)
and agarose gel electrophoresis were used to determine DNA quantity and integrity.
Urine samples
Free catch urine samples were collected by the NCSU Clinical Studies Core from canine patients
with informed owner consent. Dogs presenting to the NCSU CVMVeterinary Teaching Hospital
with one of four clinical presentations were included: 1) urothelial carcinoma of bladder and/or
urethra (n = 23), 2) prostate carcinoma (n = 3), 3) bacterial cystitis (n = 10), and 4) clinically-
healthy dogs (n = 27) were included. Of UC and PC patients, seven dogs were diagnosed through
tumor histopathology, while 19 were diagnosed based on the presence of a mass in the trigonal
region of the bladder or in the prostate gland, together with and cytological evaluation of urine
sediments and/or fine needle aspirations of the mass. Genomic DNA was isolated from urine
sediment after the cells were washed with PBS (14 dogs) or fixed in 3:1 methanol acetic acid fixa-
tive used for chromosomal analysis (49 dogs), some of which were used in the previous study
[17]. Signalment of dogs for urine samples and DNA source is shown in S1 Table.
Sanger sequencing analysis
The cBRAF V595E mutation status of all samples included in the study was evaluated by Sanger
sequencing, combined with data obtained in the past study [11]. PCR amplification was per-
formed to amplify a 391-bp DNA fragment spanning the region of cBRAF V595E as previously
described [11]. Sequencing was performed at the North Carolina State University Genome
Research Laboratory (http://research.ncsu.edu/gsl/) and data analyzed for the presence of
cBRAF V595E mutation using 4peaks software (http://nucleobytes.com/index.php/4peaks).
Digital droplet PCR analysis for cBRAF V595E mutation
A ddPCR assay, comprising forward and reverse primers and TaqMan1MGB probes for the
detection of wild-type and V595E mutated sequences, was designed with the aid of Primer
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Express Software (version 3.0.1, Life Technologies, Carlsbad, CA). Sequences and locations of
primers and probes are shown in Table 1.
The cBRAF V595E ddPCR assay comprised 20 μL of 1 x Droplet Supermix (Bio-Rad Labo-
ratories, Richmond, CA), ~20 ng of genomic DNA isolated from each patient sample, 2 U of
MseI restriction enzyme (New England Biolabs, Ipswich, MA), 500 nM of forward and reverse
primers and 250 nM of VIC- and FAM-labeled TaqMan1MGB probes for wild-type and the
V595E sequences, respectively. The PCR reaction mixtures were partitioned into an emulsion
of ~20,000 droplets (number of droplets measured: mean ± SD: 14,648 ± 2,127) using a
QX200™ ddPCR system (both from Bio-Rad). PCR was performed on T100™ Thermal Cycler
using thermal cycle condition as follows: denaturation at 95°C for 10 min; 40 cycles of 94°C for
30 sec and 59°C for 60 sec; 98°C for 10 min. Post PCR, droplets were analyzed on QX200™Dro-
plet Reader (Bio-Rad). The concentrations of wild-type and V595E sequences were calculated
on the Poisson distribution using the Quantasoft™ software Version 1.7.4 (Bio-Rad). Wild-type
control DNA (prepared from a histopathologically normal lymph node) and non-template
control reactions were included in each experiment. Up to three positive droplets for the
V595E assay were occasionally seen in the wild-type control samples in the preliminary setting
(false-positive). In this study only reactions containing at least five single occupancy V595E-
positive droplets were classified as positive in the ddPCR analysis.
To determine the detection limit of mutation fraction, serial dilutions of a plasmid contain-
ing BRAF V595E mutation were prepared. To prepare the plasmid containing V595E
sequence, PCR products obtained from a BRAF positive canine prostate carcinoma cell line,
Leo (kindly provided from Dr. T. Rosol, [18]), were cloned using a pGEM1-T Easy Vector
Systems (Promega, Madison, WI). Plasmid DNA containing the V595E sequence was used to
make a dilution series in 200 ng of wild type genomic dog DNA, where the mutation fractions
were 50%, 10%, 5%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.005% and 0.001%. Since 20 ng of DNA
may not be available in a clinical setting, to assess the effects of DNA amount in the ddPCR
reaction, a DNA dilution series of four urine DNA specimens from UC patients (1, 2, 5, 10, 20,
50 and 200 ng/reaction) was also prepared and analyzed by ddPCR.
Results
We designed a ddPCR assay for the detection of the cBRAF V595E mutation. To investigate
the performance of the cBRAF V595E ddPCR assay, plasmid DNA containing V595E sequence
was serially diluted into wild type dog genomic DNA (range of 50% to 0.001%). The assay was
able to detect the mutation when present at levels as low as 0.005% and showed a clear linearity
between calculated and measured V595E fractions (R2 = 0.999, Fig 1).
Next, we compared ddPCR and Sanger sequencing results to evaluate cBRAF V595E detec-
tion sensitivity in tissues samples. With Sanger sequencing we were able to detect the V595E
mutation in 71% (53/75) of cases; 67% (32/48) of UC and 78% (21/27) of PC. Our ddPCR
Table 1. Primers and probes used in the canine BRAF V595E ddPCR assay.
Sequence and modification Location on CFA 16
Forward primer 5'–TCATGAAGACCTCACAGTAAAAATAGGT–3' 8,296,237–8,296,264
Reverse primer 5'–TGGGACCCACTCCATCGA–3' 8,296,291–8,296,308
V595E Mut probe 5'–FAM–TCTAGCCACAGAGAAA–MGB–3' 8,296,273–8,296,288
Wt probe 5'–VIC–TAGCCACAGTGAAAT–MGB–3' 8,296,275–8,296,289
CFA, canine chromosome; Mut, mutant allele; Wt, wild-type allele
doi:10.1371/journal.pone.0144170.t001
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assay detected all of the cases (53/75) identified by Sanger sequencing and was able to detect
the mutation in additional four UC and two PC samples, increasing the frequency of the
V595E mutation overall to 79% (59/75), as 75% (36/48) and 85% (23/27) cases of canine UC
and PC, respectively. The detection limit of Sanger sequencing was 10–20% of the mutation
fraction (Fig 2A). Neither Sanger sequencing nor ddPCR analysis detected the mutation in any
of the control bladder or prostate gland tissue samples.
We then analyzed urine DNA samples from dogs with UC and PC, as well as those with cys-
titis (differential diagnosis) and clinically healthy dogs. With Sanger sequencing of urine from
UC patients, all but one urine-derived DNA sample yielded PCR products for sequencing anal-
ysis. Sequencing analysis revealed the V595E mutation in urine DNA samples of 61% (14/23)
of UC patients and 100% (3/3) of PC patients. No control urine sample (27 healthy or 10 cysti-
tis) was positive for the mutation. With ddPCR we detected the mutation in 83% (19/23) of UC
and 100% (3/3) of PC patients, including five UC samples in which the mutation was not
detected by Sanger sequencing (Fig 2B). With ddPCR the V595E mutation was not detected in
any of the healthy or cystitis dog urine samples. For the diagnosis of canine UC and PC, the
Fig 1. Performance of the cBRAF V595E assay in a serial dilution of plasmid containing V595E sequence in wild type dog gDNA. (A) Representative
two-dimensional scatter plots of the ddPCR assay in serially-diluted DNA samples. Areas in red rectangles indicate the positive reactions for cBRAF V595E
assay. The numbers shown in red rectangles indicate the number of droplets positive for the V595E mutation assay. (B) Correlation of V595E fraction
calculated by the dilutions and measured by ddPCR. The V595E mutation was detected up to 0.005% of V595E fraction. Vertical error bars represents the
95% confidence intervals calculated by the Poisson distribution.
doi:10.1371/journal.pone.0144170.g001
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Fig 2. Results of cBRAF V595E ddPCR analysis of (A) tissue and (B) urine samples of canine UC and PC patients (x-axis: each sample, y-axis:
V595E fraction%). Black and gray bars indicate UC and PC samples, respectively. Asterisks indicate samples in which the V595E mutation was not
detected in Sanger sequencing analysis.
doi:10.1371/journal.pone.0144170.g002
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overall sensitivity and specificity values of the cBRAF V595E ddPCR assay in urine DNA were
85% (22/26) and 100% (37/37), respectively. The detection rates of the cBRAF V595E mutation
in tissue and urine samples according to Sanger sequencing and ddPCR analysis are summa-
rized in Table 2.
To evaluate the relationship between the V595E mutation fraction obtained by ddPCR of
DNA obtained from tissue and urine samples, the mutation fraction was compared between six
matched tissue and urine samples. The V595E mutation was detected in both tissue and urine
specimens from the six dogs by Sanger sequencing and ddPCR. As expected, there was no or
little correlation between urine and tissue mutation fractions examined by ddPCR (Pearson
correlation coefficient, R2 = 0.138, Fig 3), reflecting the variable dilution of the mutated allele
with wild-type alleles derived from non-neoplastic (wild type) cells shed into the urine.
Since the amount of DNA obtained from urine is generally limited in a clinical setting, we
tested the performance of the ddPCR assay at a wide range of DNA input (1ng–200 ng DNA/
reaction). For this we used four urine samples with V595E mutation fractions of 0% (negative),
1.5%, 4.5% and 33%. All three V595E-positive samples produced positive results with 1–200 ng
of DNA input, whereas the V595E-negative samples remained negative. Regardless of different
amounts of DNA input, the mutation fraction showed little variance, demonstrating that the
assay was not only qualitative but also reliably quantitative at a wide range of DNA input
(Fig 4).
Discussion
Amajor challenge in the clinical management of canine UC and PC lies in accurate diagnosis.
Due to the lack of reliable, non-invasive diagnostic tests, combined with non-specific clinical
symptoms, canine UC and PC are often diagnosed at advanced stages of disease, at which time
the majority (>90%) of UC are invasive and many (>20% of UC and>40% of PC) have
metastasized [3,4]. Currently, histopathological evaluation of a tumor biopsy is considered the
gold standard for diagnosis of these canine cancers. However, the invasive nature of tumor
biopsy, risks of anesthesia, high procedure cost, and low clinical availability impede the ability
for most patients to be properly diagnosed. A non-invasive, affordable, and accessible diagnos-
tic test for these cancers is an unmet need with potential therapeutic and, therefore, prognostic
impact.
Molecular detection of genetic alterations has been widely used for cancer diagnosis in
human medicine [19]. Since somatic alteration of genetic components is often neoplasia-spe-
cific, their detection can provide a specific and objective marker for cancer diagnosis. The
Table 2. Sequencing and ddPCR analysis for V595Emutation in tissue and urine.
Specimen Disease N BRAF V595E mutation status
Sanger sequencing ddPCR
+ – + –
Tissue UC 48 32 (67%) 16 36 (75%) 12
PC 27 21 (78%) 6 23 (85%) 4
Control 38 0 38 0 38
Urine UC 23 14 (61%) 9 19 (83%) 4
PC 3 3 (100%) 0 3 (100%) 0
Control 37 0 37 0 37
UC, urothelial carcinoma; PC, prostatic carcinoma
doi:10.1371/journal.pone.0144170.t002
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cBRAF V595E mutation, corresponding to human BRAF V600E, has recently been discovered
in ~80% of canine UC and PC, rendering it of potential diagnostic significance [10,11]. In addi-
tion, BRAF inhibitors have been developed for targeted treatment of BRAFmutant tumors,
and previous studies have shown such therapies to be highly effective in several human malig-
nancies harboring the BRAF V600E mutation [20–24]. Thus, cBRAF V595E detection in urine
may be a guide for individualized medicine in canine genitourinary tumors.
In this study, we established a sensitive ddPCR-based cBRAF V595E assay and evaluated its
performance as a non-invasive molecular diagnostic technique for the detection of canine UC
and PC. Consistent with past studies, the detection sensitivity of a mutant allele by Sanger
sequencing of canine UC and PC was 10–20%. The low sensitivity of the Sanger sequencing led
to false-negative results in tissue specimens (UC: 8.3%, PC: 7.4%) that was almost three times
higher in urine samples (UC: 22%), underscoring the necessity of more sensitive methods to
detect the V595E mutation in urine samples. Using a custom ddPCR assay, we were able to
detect the V595E mutation in both tissue and urine samples of low tumor cellularity. The assay
was able to detect as low as one mutant allele in the presence of 10,000 wild type alleles (0.01%)
Fig 3. Comparison of the cBRAF V595E fraction betweenmatched tissue and urine samples of six UC/PC cases. The association between tissue and
urine was not evident.
doi:10.1371/journal.pone.0144170.g003
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and showed high linearity in quantification of the mutated allele fraction. These data indicate
that ddPCR would be a highly sensitive means of non-invasive diagnosis for canine genitouri-
nary cancers.
Although many different molecular techniques can be used to detect somatic mutations,
digital PCR is one of the most sensitive methods that can detect a point mutation when present
at levels as low as 0.001–0.01% [25] In one study, digital PCR was compared to high-resolution
melt curve analysis, pyrosequencing, and allele-specific amplification to detect the human
BRAF V600E mutation in human melanoma tumor tissues [26]. Digital PCR showed superior
detection limit compared to the other three methods, especially in tissue samples with muta-
tion load of<5%. In this study, the cBRAF V595E mutation fraction was<5% in 21% (4/19) of
mutation positive urine samples, indicating that a highly sensitive method of detection is criti-
cal for it to be clinically effective. It is of note that all canine cancer patients in this study had
full-blown disease at the time of urine collection (clinically diagnosed), suggesting that the
mutation load may be lower during early/subclinical stages of disease. The heterogeneity of
cells shed in urine necessitates employment of a sensitive method to detect the cBRAF V595E
mutation in canine UC and PC patients. Furthermore, the ddPCR assay provides not only
qualitative results (positive vs negative for V595E) but also quantitative data of tumor-derived
mutation load in urine DNA. The assay was found to be highly quantitative at wide range of
mutation fractions, enabling the quantification of tumor load in the urine of each patient dur-
ing clinical course. Although it is still unknown if the urine tumor load reflects the entire
tumor volume, the tumor load may be a potential tool to monitor treatment response and
detect minimal residual diseases after surgery.
Compared to traditional quantitative PCR (qPCR)-based methods, ddPCR is more resistant
to PCR inhibitors. It is well-known that PCR inhibitors are co-purified when isolating DNA
from urine, compromising PCR efficiencies at various degrees [27,28]. To calculate target con-
centrations, qPCR uses threshold cycles (Ct) value, which is defined as the number of cycles for
the fluorescent signal to cross a certain threshold. Since Ct values are highly affected by PCR
efficiencies, the presence of PCR inhibitors could lead to underestimation of target concentra-
tions or false-negative results on qPCR-based assays, especially for targets of a small number of
copies. In contrast, PCR efficiency has little impact on digital PCR, as digital PCR only uses
numbers of positive and negative reactions at the PCR end-point. One study demonstrated
Fig 4. Performance of the cBRAF V595E ddPCR assay at 1–200 ng DNA input. The V595E fraction
showed little variance between a wide range of DNA input. Vertical error bars represents the 95% confidence
intervals calculated by the Poisson distribution.
doi:10.1371/journal.pone.0144170.g004
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that digital PCR was 10–100 times more tolerant of inhibitors than qPCR [29]. This feature
also makes ddPCR a practical means of mutation detection in PCR inhibitor-rich urine.
One limitation of the V595E mutation as a molecular marker for canine UC and PC patients
is that ~20% of tumors do not possess the mutation, limiting the sensitivity of the ddPCR assay
around 80%. Combination of V595E mutation with sensitive molecular techniques, such as
characteristic chromosome copy number aberrations described previously, will increase the
sensitivity of the molecular analysis of urine DNA [17,30]. The complementarity of the high
specificity cBRAF V595E ddPCR assay with sensitive techniques has the potential to provide a
reliable, yet noninvasive and readily accessible diagnostic option. Furthermore, potential phar-
macologic targeting of cBRAF V595E expands the value of the assay to enable therapeutic guid-
ance. Further studies are warranted to characterize the genomic alteration of canine UC and
PC and refine the non-invasive diagnostic method to these challenging diseases, including ther-
apeutic applications.
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